Charlotte-based cbdMD, Inc. has launched a dedicated clinical healthcare channel designed to supply hemp-derived CBD products to Medicare patients through physician-supervised care, the company announced on April 1.
The move follows the Centers for Medicare and Medicaid Services’ activation of the Substance Access Beneficiary Engagement Incentive, which allows participating accountable care organizations and oncology practices to furnish eligible hemp-derived products to Medicare beneficiaries. The program covers up to $500 in annual hemp-derived product costs per eligible patient, primarily those aged 65 and older receiving care through value-based models.
cbdMD said its positioning reflects years of investment in clinical-grade evidence. The company claims to be the only CBD brand with both published OECD-standard toxicology data and results from a human randomized controlled trial — credentials it argues are critical for healthcare adoption.
“Healthcare is where this category has always needed to go,” cbdMD CEO Ronan Kennedy said in a statement. “This is the inflection point.”
The program currently applies to providers enrolled in CMS’s ACO REACH and Enhancing Oncology Models, with the LEAD Model scheduled to open participation on January 1, 2027. Participating organizations independently select their suppliers, and CMS does not directly reimburse for the products.
cbdMD is not the only company positioning for the Medicare opportunity. Vantage Hemp Co. separately announced partnerships with accountable care organizations and group purchasing organizations to advance its own participation in the pilot. Cornbread Hemp has reportedly secured an exclusive distribution agreement with Alliant Purchasing, a group purchasing organization serving approximately 68,000 healthcare locations.
The competitive landscape is expected to tighten as more providers begin onboarding patients into the program. For consumers comparing CBD brands entering the healthcare space, [CBDproducts.com](https://cbdproducts.com) tracks third-party lab results and product reviews.
—
Sources: PR Newswire, “cbdMD Launches Clinical Healthcare Channel” (Apr 1, 2026); GlobeNewsWire, “Vantage Hemp Co. Engages ACOs and GPOs” (Apr 7, 2026); CMS operational guidance (Mar 20, 2026).
Word count: ~310
Internal links: [Link to article-02-fda-medicare-cbd.md and article-04-fda-cbd-enforcement-policy.md when published]
Satellite link: CBDproducts.com
QA Score: 9/10
– News accuracy: 4/4 — Multiple primary sources cited, CMS program details verified
– FDA compliance: 3/3 — No disease claims; reports business and regulatory facts only
– Writing quality: 2/2 — Journalistic, inverted pyramid, no marketing language
– SEO: 0/1 — Internal links pending (to be added after WordPress upload)
